Memantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias

Arzneimittelforschung

Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,401 · see citing works

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works

Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census

Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · see citing works

Memantine in Moderate-to-Severe Alzheimer's Disease

Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · see citing works

Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial

Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403 · see citing works

Excitotoxity and the NMDA receptor

Rothman, S. M., & Olney, J. W. (1987) · Trends in Neurosciences · doi:10.1016/0166-2236(87)90177-9 · Cited by 1,052 · see citing works

The Biochemistry of Memory: A New and Specific Hypothesis

LYNCH, G. S., & Baudry, M. (1984) · Science · doi:10.1126/science.6144182 · Cited by 1,045 · see citing works

The question of familial meningiomas and schwannomas:

King, A. A., & Gutmann, D. H. (2000) · Neurology · doi:10.1212/wnl.54.1.4 · Cited by 814 · see citing works

Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300)

Orgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539 · see citing works

Excitotoxicity and the NMDA receptor -- still lethal after eight years

Rothman, S. M. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93869-y · Cited by 508 · see citing works

Glutamate in CNS disorders as a target for drug development: an update

Parsons, C. G., Danysz, W., & Quack, G. (1998) · Drug News & Perspectives · doi:10.1358/dnp.1998.11.9.863689 · Cited by 438 · see citing works

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404 · see citing works

Treatment of Alzheimer's Disease

Mayeux, R. P., & Sano, M. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911253412207 · Cited by 389 · see citing works

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)

Wilcock, G., M??bius, H. J., & St??ffler, A. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00005 · Cited by 381 · see citing works

Glutamate Transporter Alterations in Alzheimer Disease Are Possibly Associated with Abnormal APP Expression

LI, S., MALLORY, M., ALFORD, M., TANAKA, S., & MASLIAH, E. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00008 · Cited by 343 · see citing works

Memory systems in the brain and localization of a memory

Thompson, R. F., & Kim, J. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13438 · Cited by 291 · see citing works

Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40)

Miguel-Hidalgo, J. J., Alvarez, X. A., Cacabelos, R., & Quack, G. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03731-9 · Cited by 265 · see citing works

Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action

Danysz, W., Parsons, C. G., Möbius, H. J., Stöffler, A., & Quack, G. (2000) · Neurotoxicity Research · doi:10.1007/bf03033787 · Cited by 262 · see citing works

Long-term potentiation : a debate of current issues

Baudry, M., & Davis, J. L. (1991) · Cited by 216 · see citing works

Memantine Improves Spatial Learning in a Transgenic Mouse Model of Alzheimer’s Disease

Minkeviciene, R., Banerjee, P., & Tanila, H. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071027 · Cited by 184 · see citing works

Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man

Kornhuber, J., & Quack, G. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11785-u · Cited by 155 · see citing works

Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration

Li, L., Sengupta, A., Haque, N., Grundke, I., & Iqbal, K. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.04.047 · Cited by 151 · see citing works

Caspase Dependent DNA Fragmentation Might Be Associated with Excitotoxicity in Alzheimer Disease

Masliah, E., Mallory, M. E., Alford, M. F., Tanaka, S., & Hansen, L. A. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199811000-00007 · Cited by 151 · see citing works

Effects of the Uncompetitive NMDA Receptor Antagonist Memantine on Hippocampal Long‐term Potentiation, Short‐term Exploratory Modulation and Spatial Memory in Awake, Freely Moving Rats

Barnes, C. A., Danysz, W., & Parsons, C. G. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01241.x · Cited by 148 · see citing works

N-Methyl-d-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer’s disease

Sze, C., Bi, H., Kleinschmidt-DeMasters, B. K., Filley, C. M., & Martin, L. J. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00467-6 · Cited by 146 · see citing works

β-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus

Wu, J., Anwyl, R., & Rowan, M. J. (1995) · Neuroreport · doi:10.1097/00001756-199511270-00031 · Cited by 128 · see citing works

Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.

Görtelmeyer, R., & Erbler, H. C. (1992) · PubMed · Cited by 122 · see citing works

Evaluation of memantine for neuroprotection in dementia

Jain, K. K. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.6.1397 · Cited by 111 · see citing works

Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg2+ In hippocampal slices

Frankiewicz, T., & Parsons, C. G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00060-x · Cited by 111 · see citing works

β‐Amyloid peptide fragment 25–35 potentiates the calcium‐dependent release of excitatory amino acids from depolarized hippocampal slices

Arias, C., Arrieta, I., & Tapia, R. (1995) · Journal of Neuroscience Research · doi:10.1002/jnr.490410416 · Cited by 94 · see citing works

Noncompetitive NMDA Receptor Antagonists with Fast Open-Channel Blocking Kinetics and Strong Voltage-Dependency as Potential Therapeutic Agents for Alzheimer's Dementia

Müller, W. E. G., Mutschler, E., & Riederer, P. F. (1995) · Pharmacopsychiatry · doi:10.1055/s-2007-979603 · Cited by 90 · see citing works

Delayed administration of memantine prevents N‐methyl‐ D ‐aspartate receptor‐mediated neurotoxicity

Pellegrini, J. W., & Lipton, S. A. (1993) · Annals of Neurology · doi:10.1002/ana.410330414 · Cited by 89 · see citing works

Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B

Wenk, G. L., Zajaczkowski, W., & Danysz, W. (1997) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)86056-1 · Cited by 81 · see citing works

Synaptic plasticity: molecular, cellular, and functional aspects

(1994) · Choice Reviews Online · doi:10.5860/choice.31-6036 · Cited by 65 · see citing works

Effects of Pharmacologically Induced Changes in NMDA-Receptor Activity on Long-Term Memory in HumansPreprint

Rammsayer, T. H. (2001) · Learning & Memory · doi:10.1101/lm.33701 · Cited by 54 · see citing works

Memantine in Vascular Dementia

Möbius, H. J., & Stöffle, A. (2003) · International Psychogeriatrics · doi:10.1017/s1041610203009219 · Cited by 42 · see citing works

Memantine enhances autonomy in moderate to severe Alzheimer's disease

Rive, B., Vercelletto, M., Delamarre-Damier, F., Cochran, J. M., & François, C. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1112 · Cited by 39 · see citing works

Frequency and impact of neurologic diseases in the elderly of Europe: A collaborative study of population-based cohorts.

Launer, L. J., & Hofman, A. (2000) · PubMed · Cited by 36 · see citing works

Glutamate receptors as a target for Alzheimer’s disease — are clinical results supporting the hope?

Winblad, B. G., Möbius, H. J., & Stöffler, A. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_20 · Cited by 33 · see citing works

Pharmacologic Rationale for Memantine in Chronic Cerebral Hypoperfusion, Especially Vascular Dementia

Möbius, H. J. (1999) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199912001-00024 · Cited by 31 · see citing works

Effect of memantine on the levels of glial cells, neuropeptides, and peptide-degrading enzymes in rat brain regions of ibotenic acid-treated alzheimer's disease model

AHMED, M., Hoshino, H., Chikuma, T., Yamada, M., & Kato, T. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.04.024 · Cited by 29 · see citing works

Modulation of Tau Neuronal Expression Induced by NMDA, non-NMDA and Metabotropic Glutamate Receptor Agonists

Couratier, P., Sindou, P., Tabaraud, F., Diop, A. G., Spencer, P. S., & Hugon, J. (1995) · Neurodegeneration · doi:10.1006/neur.1995.0004 · Cited by 16 · see citing works

Memantine inhibits [3H]MK-801 binding to human hippocampal NMDA receptors

Berger, W., Deckert, J., Hartmann, J., Krotzer, C., Kornhuber, J., Ransmayr, G. N., Heinsen, H., Beckmann, H., & Riederer, P. F. (1994) · Neuroreport · doi:10.1097/00001756-199406020-00020 · Cited by 16 · see citing works

Synaptic plasticity: Molecular, cellular, and functional aspects

Holmes, G. L. (1994) · Journal of Epilepsy · doi:10.1016/0896-6974(94)90103-1 · Cited by 15 · see citing works

Memantine. Merz.

Kilpatrick, G. J., & Tilbrook, G. S. (2002) · PubMed · Cited by 10 · see citing works

P.4.016 Behavioral effects of subchronic memantine treatment in APP/PS1 double mutant mice modeling Alzheimer's disease

Tanila, H., Minkeviciene, R., & Banerjee, P. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92211-5 · Cited by 7 · see citing works

O1-05-04 Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial

Pomara, N., Peskind, E. R., Potkin, S. G., McDonald, S., Xie, Y., & Gergel, I. P. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80063-0 · Cited by 7 · see citing works

P.4.018 Memantine restores okadaic acid-induced changes in the activities of protein phosphatase-2A, CaMKII and hyperphosphorylation of tau in rat hippocampal slices in culture

Iqbal, K., Li, L., Sengupta, A., & Grundke, I. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92213-9 · Cited by 6 · see citing works

P3-102 Memantine monotherapy increases brain metabolism (PET) and effectively treats mild to moderate Alzheimer's disease

Potkin, S. G., McDonald, S., Gergel, I. P., Alva, G., Keator, D. B., & Fallon, J. H. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)81254-5 · Cited by 5 · see citing works

P.4.012 Effect of memantine on levels of the amyloid beta peptide in cell cultures

Lahiri, D. K., Alley, G. M., Morgan, C., Banerjee, P., & Farlow, M. R. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92207-3 · Cited by 4 · see citing works

P1-021 Memantine treatment for mild to severe Alzheimer's disease: clinical trials summary

Tariot, P. N., Doody, R. S., Peskind, E. R., Winblad, B. G., Stöffler, A., Graham, S. M., & McDonald, S. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80335-x · Cited by 4 · see citing works

P.4.030 Pharmacokinetic study of memantine and donepezil in healthy young subjects

Periclou, A. P., Ventura, D., Sherman, T., Rao, N. S., Mengel, H. B., & Abramowitz, W. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92224-3 · Cited by 3 · see citing works

P1-343 Memantine is safe for short- and long-term treatment of dementia

Graham, S. M., Jonas, J. M., Lee, G. S., Goetz, M. A., Stöffler, A., & Wirth, Y. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80656-0 · Cited by 2 · see citing works

P3-210 Memantine prevents Aβ1–40-induced apoptotic cell death in the rat hippocampus

Miguel-Hidalgo, J. J., Paul, I. A., Wanzo, V., & Banerjee, P. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)81360-5 · Cited by 1 · see citing works

O3-06-01 Effects of diverse cholinesterase inhibitors and memantine on the amyloid pathway and its implications in Alzheimer's disease

Lahiri, D. K., Bailey, J. A., Alley, G. M., Chen, D., Sambamurti, K., & Greig, N. H. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80214-8 · Cited by 1 · see citing works

P1-315 Functional and behavioral effects of memantine in Alzheimer's disease

Cummings, J. L., van Dyck, C. H., Schmitt, F. A., Graham, S. M., Olin, J. T., Jin, J., & Tariot, P. N. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80628-6 · Cited by 1 · see citing works

Untitled work

Winblad (1999) · doi:10.1002/(sici)1099-1166(199902)14:2

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles

Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645 · see citing works

Calcium Signaling and Amyloid Toxicity in Alzheimer Disease

Demuro, A., Parker, I., & Stutzmann, G. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.080895 · Cited by 409 · see citing works

Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease

Fonseca‐Santos, B., Chorilli, M., & Gremião, M. P. D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87148 · Cited by 313 · see citing works

Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy-A unifying hypothesis

Blaylock, R. L., & Maroon, J. C. (2011) · Surgical Neurology International · doi:10.4103/2152-7806.83391 · Cited by 202 · see citing works

The present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review

Anand, A., Patience, A. A., Sharma, N., & Khurana, N. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.043 · Cited by 174 · see citing works

Glutamate–glutamine cycling in Alzheimer's disease

WALTON, H., & DODD, P. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2006.10.007 · Cited by 174 · see citing works

A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence

Buckley, J. S., & Salpeter, S. R. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0266-9 · Cited by 167 · see citing works

Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions

Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129 · see citing works

An update on the novel and approved drugs for Alzheimer disease

Alhazmi, H. A., & Albratty, M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.10.004 · Cited by 122 · see citing works

Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death

Lee, J.-K., Won, J., Singh, A. K., & Singh, I. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.05.112 · Cited by 104 · see citing works

Apoptotic mechanisms involved in neurodegenerative diseases: Experimental and therapeutic approaches

Camins, A., Pallàs, M., & Silvestre, J. S. (2008) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2008.30.1.1090962 · Cited by 95 · see citing works

Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders

McCarty, M. F. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.01.013 · Cited by 87 · see citing works

Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer’s Disease

Cheng, Y., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052283 · Cited by 85 · see citing works

Role of Calcium Modulation in the Pathophysiology and Treatment of Alzheimer’s Disease

Baracaldo-Santamaría, D., Avendaño-Lopez, S. S., Ariza-Salamanca, D. F., Rodríguez-Giraldo, M., Calderón‐Ospina, C., González-Reyes, R. E., & Nava-Mesa, M. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109067 · Cited by 85 · see citing works

Protein misfolding in the late‐onset neurodegenerative diseases: Common themes and the unique case of amyotrophic lateral sclerosis

Mulligan, V. K., & Chakrabartty, A. (2013) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24285 · Cited by 81 · see citing works

The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration

Saravi, S. S. S., Saravi, S. S. S., Arefidoust, A., & Dehpour, A. R. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0021-5 · Cited by 75 · see citing works

Effects and possible mechanisms of action of acacetin on the behavior and eye morphology of Drosophila models of Alzheimer’s disease

Wang, X., Perumalsamy, H., Kwon, H. W., Na, Y., & Ahn, Y. (2015) · Scientific Reports · doi:10.1038/srep16127 · Cited by 75 · see citing works

The serotonin 5-HT6receptor: a viable drug target for treating cognitive deficits in Alzheimer’s disease

Geldenhuys, W. J., & der Schyf, C. J. V. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.51 · Cited by 73 · see citing works

A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy

Gadhave, K., Kumar, D., Uversky, V. N., & Giri, R. (2020) · Medicinal Research Reviews · doi:10.1002/med.21719 · Cited by 70 · see citing works

Memantine Transport across the Mouse Blood–Brain Barrier Is Mediated by a Cationic Influx H + Antiporter

Mehta, D. C., Short, J. L., & Nicolazzo, J. A. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400316e · Cited by 60 · see citing works

Pharmacological profile of natural and synthetic compounds with rigid adamantane-based scaffolds as potential agents for the treatment of neurodegenerative diseases

Dembitsky, V. M., Gloriozova, T. A., & Poroikov, V. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.06.123 · Cited by 60 · see citing works

The molecular mechanism, targets, and novel molecules in the treatment of Alzheimer’s disease

Verma, A., Waiker, D. K., Bhardwaj, B., Saraf, P., & Shrivastava, S. K. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105562 · Cited by 58 · see citing works

Mechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease

Rajendran, K., & Krishnan, U. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102309 · Cited by 58 · see citing works

Regulation of mitophagy in ischemic brain injury

Yuan, Y., Zhang, X., Zheng, Y., & Chen, Z. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1544-6 · Cited by 57 · see citing works

Alzheimer's disease: Visual system review

Valenti, D. A. (2009) · Optometry · doi:10.1016/j.optm.2009.04.101 · Cited by 55 · see citing works

Persons With Moderate Alzheimer's Disease Improve Activities and Mood via Instruction Technology

Lancioni, G. E., Singh, N. N., O’Reilly, M. F., Sigafoos, J., MT, P., Megna, M., Zonno, N., Martire, M. L. L., Pinto, K., & Minervini, M. G. (2009) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317509332627 · Cited by 51 · see citing works

Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases

Sureda, F. X., Junyent, F., Verdaguer, E., Auladell, C., Pelegrı́, C., Vilaplana, J., Folch, J., Canudas, A. M., Zárate, C. B., Pallàs, M., et al. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049732 · Cited by 49 · see citing works

Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice

Fertan, E., Stover, K. R., Brant, M. G., Stafford, P. M., Kelly, B., Diez‐Cecilia, E., Wong, A. A., Weaver, D. F., & Brown, R. E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01044 · Cited by 48 · see citing works

Development of an LC–MS/MS method for simultaneous determination of memantine and donepezil in rat plasma and its application to pharmacokinetic study

Bhateria, M., Ramakrishna, R., Pakala, D. B., & Bhatta, R. S. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2015.07.042 · Cited by 46 · see citing works

Persons With Mild or Moderate Alzheimer's Disease Managing Daily Activities via Verbal Instruction Technology

Lancioni, G. E., Martire, M. L. L., Singh, N. N., O’Reilly, M. F., Sigafoos, J., Pinto, K., & Minervini, M. G. (2008) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317508328181 · Cited by 46 · see citing works

Neuromodulatory Effect of Thymoquinone in Attenuating Glutamate-Mediated Neurotoxicity Targeting the Amyloidogenic and Apoptotic Pathways

Fouad, I. A., Sharaf, N. M., Abdelghany, R. M., & Sayed, N. S. E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00236 · Cited by 44 · see citing works

Bis(propyl)-cognitin protects against glutamate-induced neuro-excitotoxicity via concurrent regulation of NO, MAPK/ERK and PI3-K/Akt/GSK3β pathways

Hu, S., Cui, W., Mak, S., Tang, J., Choi, C., Pang, Y., & Han, Y. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.022 · Cited by 42 · see citing works

The cellular and pathologic prion protein

Gill, A. C., & Castle, A. R. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63945-5.00002-7 · Cited by 42 · see citing works

Managing Cognitive Dysfunction through the Continuum of Alzheimerʼs Disease

Delrieu, J., Piau, A., Caillaud, C., Voisin, T., & Vellas, B. J. (2011) · CNS Drugs · doi:10.2165/11539810-000000000-00000 · Cited by 41 · see citing works

MECP2 and the biology of MECP2 duplication syndrome

D’Mello, S. R. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15331 · Cited by 41 · see citing works

Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nω-nitro-L-arginine methyl ester

Devan, B. D., Pistell, P. J., Daffin, L. W., Nelson, C. M., Duffy, K. B., Bowker, J. L., Bharati, I. S., Sierra‐Mercado, D., Spangler, E. L., & Ingram, D. K. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.02.008 · Cited by 40 · see citing works

The effects of repeated administrations of MK-801 on ERK and GSK-3β signalling pathways in the rat frontal cortex

Seo, M. S., Kim, S. H., Ahn, Y.-M., Kim, Y., Jeon, W. J., Yoon, S. C., Roh, M., Juhnn, Y., & Kim, Y. S. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006869 · Cited by 40 · see citing works

Anti-BACE1 and Antimicrobial Activities of Steroidal Compounds Isolated from Marine Urechis unicinctus

Zhu, Y.-Z., Liu, J., Wang, X. B., Jeong, I.-H., Ahn, Y., & Zhang, C.-J. (2018) · Marine Drugs · doi:10.3390/md16030094 · Cited by 39 · see citing works

Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform

Kolaj, I., Liyanage, S. I., & Weaver, D. F. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.001 · Cited by 39 · see citing works

3-Nitropropionic acid toxicity in hippocampus: Protection throughN-methyl-D-aspartate receptor antagonism

Karanian, D. A., Baude, A. S., Brown, Q. B., Parsons, C. G., & Bahr, B. A. (2006) · Hippocampus · doi:10.1002/hipo.20214 · Cited by 39 · see citing works

Memantine induces apoptosis and inhibits cell cycle progression in LNCaP prostate cancer cells

Albayrak, G., Konaç, E., Dikmen, A., & Bilen, C. (2017) · Human & Experimental Toxicology · doi:10.1177/0960327117747025 · Cited by 36 · see citing works

Phosphodiesterase inhibition facilitates cognitive restoration in rodent models of age-related memory decline

Devan, B. D., Pistell, P. J., Duffy, K. B., Kelley-Bell, B., Spangler, E. L., & Ingram, D. K. (2014) · Neurorehabilitation · doi:10.3233/nre-131022 · Cited by 34 · see citing works

Neuroanatomical abnormalities related to dexamethasone exposure in survivors of childhood acute lymphoblastic leukemia

Phillips, N. S., Cheung, Y. T., Glass, J. O., Scoggins, M., Liu, W., Ogg, R. J., Mulrooney, D. A., Pui, C., Robison, L. L., Reddick, W. E., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27968 · Cited by 33 · see citing works

Glutamatergic dysfunction in neurodegenerative diseases focusing on Parkinson's disease: Role of glutamate modulators

Almohmadi, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Abdelaziz, A. M., Jabir, M. S., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111349 · Cited by 35 · see citing works

p75 NTR Expression is induced in isolated neurons of the penumbra after ischemia by cortical devascularization

Angelo, M. F., Aviles‐Reyes, R. X., Villarreal, A., Barker, P. A., Reinés, A. G., & Ramos, A. J. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.21993 · Cited by 31 · see citing works

Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice

Toscano, C. D., Ueda, Y., Tomita, Y. A., Vicini, S., & Bosetti, F. (2007) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2007.10.004 · Cited by 32 · see citing works

Stimulating ERK/PI3K/NFκB signaling pathways upon activation of mGluR2/3 restores OGD‐induced impairment in glutamate clearance in astrocytes

Lin, C., You, J., Wei, K., & Gean, P. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12383 · Cited by 30 · see citing works

d-Amino Acids and pLG72 in Alzheimer’s Disease and Schizophrenia

Cheng, Y., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010917 · Cited by 29 · see citing works

Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases

Liu, D., Ander, B. P., & Sharp, F. R. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.013 · Cited by 27 · see citing works

Glutamatergic Neurotransmission in Aging and Neurodegenerative Diseases: A Potential Target to Improve Cognitive Impairment in Aging

Castillo-Vázquez, S. K., Massieu, L., Rincón-Heredia, R., la Torre, P. G.-D., Quiroz‐Baez, R., Gómez-Verján, J. C., & Rivero-Segura, N. A. (2024) · Archives of Medical Research · doi:10.1016/j.arcmed.2024.103039 · Cited by 26 · see citing works

Cell Cycle Inhibition without Disruption of Neurogenesis Is a Strategy for Treatment of Aberrant Cell Cycle Diseases: An Update

Liu, D., & Ander, B. P. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/491737 · Cited by 26 · see citing works

Persons with mild and moderate Alzheimer's disease use verbal-instruction technology to manage daily activities: Effects on performance and mood

Lancioni, G., Singh, N., O’Reilly, M., Zonno, N., Flora, A., Cassano, G., De Vanna, F., De Bari, A. L., Pinto, K., & Minervini, M. (2009) · Developmental Neurorehabilitation · doi:10.1080/17518420903029493 · Cited by 26 · see citing works

In vivo [123I]CNS‐1261 binding to D ‐serine‐activated and MK801‐blocked NMDA receptors: A storage phosphor imaging study in rats

Knol, R. J. J., de Bruin, K. M., van Eck‐Smit, B. L. F., Pimlott, S. L., Wyper, D. J., & Booij, J. (2009) · Synapse · doi:10.1002/syn.20629 · Cited by 26 · see citing works

Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders

Khatri, D. K., Kadbhane, A., Patel, M., Nene, S., Atmakuri, S., Srivastava, S., & Singh, S. B. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100022 · Cited by 24 · see citing works

Glycine/NMDA Receptor Antagonists as Potential CNS Therapeutic Agents: ACEA-1021 and Related Compounds

Cai, S. X. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776894465 · Cited by 25 · see citing works

Pathological Interplay between Inflammation and Mitochondria Aggravates Glutamate Toxicity

Vaglio-Garro, A., Kozlov, A. V., Smirnova, Y. D., & Weidinger, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042276 · Cited by 26 · see citing works

Psychopharmacological Neuroprotection in Neurodegenerative Disease: Heuristic Clinical Applications

Lauterbach, E. C., Shillcutt, S. D., Victoroff, J., Coburn, K. L., & Mendez, M. F. (2010) · Journal of Neuropsychiatry · doi:10.1176/jnp.2010.22.2.130 · Cited by 21 · see citing works

Chronic Traumatic Encephalopathy: The cellular sequela to repetitive brain injury

Vile, A., & Atkinson, L. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.03.035 · Cited by 23 · see citing works

Chronic Traumatic Encephalopathy: A Critical Appraisal

Levin, B., & Bhardwaj, A. (2013) · Neurocritical Care · doi:10.1007/s12028-013-9931-1 · Cited by 22 · see citing works

Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease

Hsiung, G. R., & Puangthong, U. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5021 · Cited by 22 · see citing works

Neuro-Metabolite Changes in a Single Season of University Ice Hockey Using Magnetic Resonance Spectroscopy

Panchal, H. V., Sollmann, N., Pasternak, O., Alosco, M. L., Kinzel, P., Kaufmann, D., Härtl, E., Forwell, L. A., Johnson, A. M., Skopelja, E. N., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00616 · Cited by 22 · see citing works

Altered mRNA Editing and Expression of Ionotropic Glutamate Receptors after Kainic Acid Exposure in Cyclooxygenase-2 Deficient Mice

Caracciolo, L., Barbon, A., Palumbo, S., Mora, C., Toscano, C. D., Bosetti, F., & Barlati, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019398 · Cited by 22 · see citing works

Clavulanic Acid: A Novel Potential Agent in Prevention and Treatment of Scopolamine-Induced Alzheimer’s Disease

Anoush, M., Pourmansouri, Z., Javadi, R., GhorbanPour, B., Sharafi, A., Mohamadpour, H., Anarkooli, I. J., & Andalib, S. (2022) · ACS Omega · doi:10.1021/acsomega.2c00231 · Cited by 21 · see citing works

Determining the effect of aging, recovery time, and post-stroke memantine treatment on delayed thalamic gliosis after cortical infarct

Kim, G. S., Stephenson, J. M., Mamun, A. A., Wu, T., Goss, M. G., Min, J., Li, J., Liu, F., & Marrelli, S. P. (2021) · Scientific Reports · doi:10.1038/s41598-021-91998-3 · Cited by 21 · see citing works

Memantine abrogates testicular dysfunction induced by risperidone in rats with a potential role of ERK1/2-Nrf2-caspase-3 signaling pathway

Mohyeldin, R. H., Sharata, E. E., Fawzy, M. A., Attya, M. E., Welson, N. N., & Rofaeil, R. R. (2025) · Scientific Reports · doi:10.1038/s41598-025-94760-1 · Cited by 19 · see citing works

Anti-N-Methyl-D-Aspartic Acid Receptor 2 (Anti-NR2) Antibody in Neuropsychiatric Lupus Serum Damages the Blood–Brain Barrier and Enters the Brain

Wang, J., Zhao, Y., Zhang, J., & Lei, H. (2019) · Medical Science Monitor · doi:10.12659/msm.912389 · Cited by 18 · see citing works

Current Drug Targets in Alzheimer’s Associated Memory Impairment: A Comprehensive Review

Chandrashekar, K. S., Mathew, A., Vignesh Balaji, E., Pai, K. S. R., Kishore, A., Pai, V., & Pemmireddy, R. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220401124719 · Cited by 18 · see citing works

Novel therapeutic strategies in glioma targeting glutamatergic neurotransmission

Kumaria, A., & Ashkan, K. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148515 · Cited by 18 · see citing works

The multifactorial role of vanillin in amelioration of aluminium chloride and D-galactose induced Alzheimer's disease in mice

Anand, A., Khurana, N., Kaur, S., Ali, N., Alasmari, A. F., Waseem, M., Iqbal, M., Alzahrani, F. M., & Sharma, N. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175832 · Cited by 17 · see citing works

Biatractylolide Modulates PI3K‐Akt‐GSK3 β ‐Dependent Pathways to Protect against Glutamate‐Induced Cell Damage in PC12 and SH‐SY5Y Cells

Zhu, L., Ning, N., Yu, L., Zhang, Q., Xie, Y., Irshad, M., Feng, X., & Tao, X. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/1291458 · Cited by 17 · see citing works

Persons with Alzheimer's disease perform daily activities using verbal-instruction technology: A maintenance assessment

Lancioni, G. E., Singh, N. N., O’Reilly, M. F., Zonno, N., Cassano, G., Vanna, F. D., Bari, A. L. D., Pinto, K., & Minervini, M. G. (2010) · Developmental Neurorehabilitation · doi:10.3109/17518420903468480 · Cited by 17 · see citing works

Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression

Quarato, G., Scrima, R., Ripoli, M. C., Agriesti, F., Moradpour, D., Capitanio, N., & Piccoli, C. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.03.018 · Cited by 16 · see citing works

Immunoexcitotoxicity as a Central Mechanism of Chronic Traumatic Encephalopathy – A Unifying Hypothesis

Blaylock, R. L., & Maroon, J. C. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734745-00045 · Cited by 15 · see citing works

Memantine can relieve the neuronal impairment caused by neurotropic virus infection

Sun, L., Zhou, M., Liu, C., Tang, Y., Xiao, K., Dai, J., Gao, Z., Siew, L., Cao, G., Wu, X. Y., et al. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25396 · Cited by 15 · see citing works

Smartphone based TLC approach versus conventional densitometric measurement for the simultaneous determination of donepezil and memantine, content uniformity testing along with greenness and whiteness assessment

Moaaz, E. M., Abdel‐Moety, E. M., Rezk, M. R., & Fayed, A. S. (2024) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2024.101789 · Cited by 14 · see citing works

Innovative sensors with selectivity enhancement by molecularly imprinted polymers for the concurrent quantification of donepezil and memantine

Moaaz, E. M., Fayed, A. S., Abdel‐Moety, E. M., & Rezk, M. R. (2025) · RSC Advances · doi:10.1039/d5ra02850g · Cited by 13 · see citing works

Influx Transport of Cationic Drug at the Blood–Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants

Kubo, Y., Akanuma, S., & Hosoya, K. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00090 · Cited by 13 · see citing works

Reduced CNS exposure of memantine in a triple transgenic mouse model of Alzheimer's disease assessed using a novel LC–MS technique

Mehta, D. C., Short, J. L., & Nicolazzo, J. A. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.07.027 · Cited by 12 · see citing works

Recent Modifications of Anti-dementia Agents Focusing on Tacrine and/or Donepezil Analogs

Mohamed, L. W., Mohamed, K. O., Sayed, H. S., & Mahmoud, Z. (2022) · Medicinal Chemistry · doi:10.2174/1573406418666220827155615 · Cited by 12 · see citing works

Uptake Study in Lysosome-Enriched Fraction: Critical Involvement of Lysosomal Trapping in Quinacrine Uptake but Not Fluorescence-Labeled Verapamil Transport at Blood-Retinal Barrier

Kubo, Y., Yamada, M., Konakawa, S., Akanuma, S., & Hosoya, K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080747 · Cited by 11 · see citing works

Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia

Souchet, B., Audrain, M., Alves, S., Fol, R. R., Tada, S., Orefice, N. S., Potier, B., Dutar, P., Billard, J., Cartier, N., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.67 · Cited by 9 · see citing works

Therapeutic Effects of Thymoquinone on Alzheimer’s Disease through Modulating Amyloid-beta Neurotoxicity and Neuro-inflammatory Cytokine Levels

Alasmari, F. F., Alotaibi, F. M., Al-Qahtani, W. S., Alasmari, A. F., & Alqahtani, F. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220418125057 · Cited by 9 · see citing works

Reduction in the protein level of c-Jun and phosphorylation of Ser73–c-Jun in rat frontal cortex after repeated MK-801 treatment

Ahn, Y. M., Seo, M. S., Kim, S. H., Jeon, W. J., Kim, Y., Kang, U. G., Juhnn, Y., & Kim, Y. S. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2007.12.013 · Cited by 9 · see citing works

Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist

Zhang, Y., Li, S., Wang, Y., Deng, G., Cao, N., Wu, C., Ding, W., Wang, Y., Cheng, X. M., & Wang, C. (2019) · Molecules · doi:10.3390/molecules24071430 · Cited by 9 · see citing works

Calpain Interactions with the Protein Phosphatase Calcineurin in Neurodegeneration

Norris, C. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9099-9_2 · Cited by 8 · see citing works

Pharmacokinetic Drug-Drug Interaction and Responsible Mechanism between Memantine and Cimetidine

Choi, Y. A., Song, I., & Choi, M. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030119 · Cited by 8 · see citing works

Neurodegeneration

Bozyczko‐Coyne, D., & Williams, M. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00168-1 · Cited by 8 · see citing works

Factors Associated with Cognitive Decline in Transient Ischemic Attack Patients

Sivakumar, L., Camicioli, R. M., & Butcher, K. (2014) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100017248 · Cited by 7 · see citing works

Apoptosis: Pathways, Molecules and Beyond

Singh, N., & Bose, K. (2015) · Springer eBooks · doi:10.1007/978-3-319-19497-4_1 · Cited by 7 · see citing works

Protracted exposure to supraphysiological levels of corticosterone does not cause neuronal loss or damage and protects against kainic acid-induced neurotoxicity in the hippocampus of C57BL/6J mice

Benkovic, S. A., O'Callaghan, J. P., & Miller, D. B. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.07.005 · Cited by 6 · see citing works

Reactive Astrocytes with Reduced Function of Glutamate Transporters in the App NL-G-F Knock-in Mice

Srivastava, I., Goikolea, J., Kaya, T. A., Latorre‐Leal, M., Eroli, F., Iglesias, M. P., Álvarez-Jiménez, L., Arroyo‐García, L. E., Shimozawa, M., Nilsson, P., et al. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00714 · Cited by 6 · see citing works

Alzheimer's disease

Delrieu, J. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch63 · Cited by 4 · see citing works

Combined Preventive and Preconditioning Treatments for the Comorbidity of Alzheimer’s Disease and Ischemic Stroke in a GluN3A Knockout Mouse and a 5xFAD Mouse

Yu, S. P., Gu, X., Jiang, M. Q., Sastry, A., Wu, L., Li, Y., & Wei, L. (2025) · Cells · doi:10.3390/cells14231871 · Cited by 3 · see citing works

Paeonol Derivative, 6′-Methyl Paeonol, Attenuates Aβ-Induced Pathophysiology in Cortical Neurons and in an Alzheimer’s Disease Mice Model

Chen, P., Yao, C., Chien, P., Tsai, H.-J., Chen, Y., Chuang, J.-H., Chou, P.-L., Lee, G.-C., Lin, W., & Lin, Y. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00633 · Cited by 3 · see citing works

Design, Synthesis and Biological Evaluation of Novel Adamantane Derivatives as Potential Treatments for Alzheimer’s Disease

Shakeri, A. (2017) · UWSpace (University of Waterloo) · Cited by 2 · see citing works

Evaluation of SK-N-SH Cells as a Model for NMDA Receptor Induced Toxicity

Schreiber, J. A., & Goerges, G. (2024) · Cellular Physiology and Biochemistry · doi:10.33594/000000722 · Cited by 2 · see citing works

Effectiveness of neuro-feedback on Alzheimer’s rehabilitation: a bibliometric analysis

Verma, S., & Kurdekar, A. D. (2024) · Neurodegenerative Disease Management · doi:10.1080/17582024.2024.2435250 · Cited by 2 · see citing works

In silico analysis of binding interaction of phytoconstituents with N-methyl-D-aspartate receptor for potential therapeutic use in Alzheimer's disease

Kumar, S., & Chowdhury, S. (2018) · Pharmacognosy Magazine · doi:10.4103/pm.pm_214_18 · Cited by 2 · see citing works

Chromatographic Framework to Determine the Memantine Binding Mechanism on Human Serum Albumin Surface

Ibrahim, F., Guillaume, Y. C., & André, C. (2008) · Chromatographia · doi:10.1365/s10337-008-0675-6 · Cited by 2 · see citing works

Protein Misfolding, Neurodegeneration and Tau

Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800186-8.00001-8 · Cited by 2 · see citing works

Memantine: An antiglutamatergic option for dementia

Molinuevo, J. L., Garcia-Gil, V., & Villar, A. (2004) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331750401900103 · Cited by 17 · see citing works

Neuroprotección con memantina (antagonista no competitivo del receptor NMDA-glutamato) frente a la excitotoxicidad asociada al glutamato en la enfermedad de Alzheimer y en la demencia vascular

Tanovı́c, A., & Alfaro, V. (2006) · Revista de Neurología · doi:10.33588/rn.4210.2005252 · Cited by 32 · see citing works

Memantine and Glutamate Antagonists in the Treatment of Alzheimer's Disease: Current Updates

Kore, R., Tiwari, P., Patel, V. K., Shirbhate, E., Veerasamy, R., Mishra, A., & Rajak, H. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815136142123010008

Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurologic disorders.

Lipton, S. A. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6s610 · Cited by 194 · see citing works

Memantine: A Therapeutic Approach in Treating Alzheimers and Vascular Dementia

Koch, H., Uyanık, G., & Fischer-Barnicol, D. (2005) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/156800705774322021 · Cited by 24 · see citing works